Only one study reported in vivo anti-tumor effects of the seven benzimidazoles, in which OBZ (25 mg/kg p.o., in mice) was shown to increase the expression levels of miRNA-204 and p53, in addition to exerting repressing effects on androgen receptors and prostate-specific androgens in prostate 22Rv1 tumors [31]. The gene discussed is TP53; the disease is neoplasm.